This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
A study providing some of the first real-world data on RSV effectiveness shows that adults aged 60 years and older who received RSV vaccination were up to 80% less likely to be hospitalized with RSV than those who were unvaccinated. RSV causes 100,000–160,000 hospitalizations annually in adults ages 60 and older. Vaccination against RSV for adults was first recommended in June 2023, and these data contributed to updated Centers for Disease Control and Prevention’s (CDC’s) recommendations released in June 2024.
The findings have been published in The Lancet: “Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: A test-negative design analysis”.
Westat staff members Janet A. Watts, PhD, Patrick K. Mitchell, ScD, Elizabeth A.K. Rowley, DrPH, Sarah E. Reese, PhD, and Sarah W. Ball, ScD, were among the coauthors. The data come from CDC’s VISION Network. Westat supports data management and analysis in this work.
Focus Areas
Clinical Research Disease Surveillance Network Coordinating Centers Public Health Real-World DataCapabilities
Data Collection